GeoVax Labs Inc (GOVX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $928,290
Last updated: Nov 17, 2026 at 11:04 AM ET
GeoVax Labs Inc (GOVX) Earnings: Report Dates and Results
GeoVax Labs (GOVX) is expected to report earnings on Apr 13, 2027. In the quarter ended Sep 30, 2026, GeoVax Labs reported EPS of -$10.56, above the -$24.58 estimate. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GOVX has an expected report date of Apr 13, 2027.
GOVX Earnings Call
The latest GOVX earnings call transcript on file is labeled 2025Q3.
Read the 2025Q3 transcriptEarnings History
Of the 33 quarters below that had an estimate, GOVX beat 16, missed 7 and matched 10. The widest gap in the table came in the quarter ended Dec 31, 2021, when EPS landed 457.50% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$10.56 | -$24.58 | N/A | +57.04% | Beat | N/A | 1 | N/A | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.97 | -$2.16 | -$2.88 - -$1.43 | +55.09% | Beat | N/A | 2 | N/A | Jul 27, 2026 | N/A |
| Mar 31, 2026 | -$2.62 | -$0.84 | -$1.60 - -$0.09 | -211.90% | Miss | N/A | 2 | 1 up, 0 down | Apr 2, 2026 | N/A |
| Sep 30, 2025 | -$7.75 | -$6.62 | -$8.00 - -$5.75 | -17.07% | Miss | N/A | 4 | 3 up, 0 down | Nov 13, 2025 | N/A |
| Jun 30, 2025 | -$8.75 | -$9.00 | N/A | +2.78% | Beat | N/A | N/A | 0 up, 0 down | Jul 28, 2025 | $852282 |
| Mar 31, 2025 | -$11.25 | -$16.44 | N/A | +31.57% | Beat | N/A | N/A | 0 up, 0 down | May 1, 2025 | $1.64M |
| Dec 31, 2024 | -$0.30 | -$0.77 | N/A | +60.94% | Beat | N/A | N/A | 0 up, 0 down | Mar 27, 2025 | $864415 |
| Sep 30, 2024 | -$22.75 | -$32.90 | -$51.00 - -$22.75 | +30.85% | Beat | N/A | 4 | 0 up, 0 down | Nov 12, 2024 | $2.79M |
| Jun 30, 2024 | -$49.75 | -$84.12 | -$145.50 - -$52.50 | +40.86% | Beat | N/A | 4 | 0 up, 0 down | Aug 6, 2024 | $300677 |
| Mar 31, 2024 | -$2.47 | -$5.56 | -$5.56 - -$5.56 | +55.58% | Beat | N/A | 1 | 0 up, 0 down | May 14, 2024 | N/A |
| Dec 31, 2023 | -$98.50 | -$105.00 | -$1,911.54 - $26.24 | +6.19% | Beat | N/A | 3 | 1 up, 0 down | Feb 29, 2024 | $103912 |
| Sep 30, 2023 | -$120.00 | -$90.00 | -$93.70 - -$86.21 | -33.33% | Miss | N/A | 3 | 0 up, 0 down | Nov 8, 2023 | N/A |
| Jun 30, 2023 | -$82.50 | -$63.75 | N/A | -29.41% | Miss | N/A | 4 | 0 up, 0 down | Aug 9, 2023 | N/A |
| Mar 31, 2023 | -$56.25 | -$84.37 | -$89.96 - -$59.97 | +33.33% | Beat | N/A | 3 | 0 up, 0 down | May 4, 2023 | N/A |
| Dec 31, 2022 | -$0.20 | -$0.20 | -$0.25 - -$0.17 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Mar 23, 2023 | N/A |
| Sep 30, 2022 | -$63.75 | -$45.00 | N/A | -41.67% | Miss | N/A | 1 | 0 up, 0 down | Nov 9, 2022 | N/A |
| Jun 30, 2022 | -$67.50 | -$112.50 | N/A | +40.00% | Beat | N/A | N/A | 0 up, 0 down | Aug 3, 2022 | N/A |
| Mar 31, 2022 | -$127.50 | -$116.25 | N/A | -9.68% | Miss | N/A | 1 | 0 up, 0 down | Apr 27, 2022 | $81526 |
| Dec 31, 2021 | -$2.23 | -$0.40 | -$0.40 - -$0.40 | -457.50% | Miss | -100.8% | 1 | 0 up, 0 down | Mar 9, 2022 | $164962 |
| Sep 30, 2021 | -$116.25 | -$138.75 | N/A | +16.22% | Beat | N/A | 1 | N/A | Nov 11, 2021 | $30414 |
| Jun 30, 2021 | -$78.75 | -$161.25 | N/A | +51.16% | Beat | N/A | 1 | N/A | Aug 11, 2021 | $79708 |
| Mar 31, 2021 | -$0.29 | -$0.29 | N/A | 0.00% | In line | N/A | N/A | N/A | May 6, 2021 | $110417 |
| Dec 31, 2020 | $266.25 | -$15.00 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 23, 2021 | $251621 |
| Sep 30, 2020 | -$0.73 | -$0.73 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 5, 2020 | $415458 |
| Jun 30, 2020 | -$0.03 | -$0.03 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 10, 2020 | $440602 |
| Mar 31, 2020 | -$0.13 | -$0.13 | N/A | 0.00% | In line | N/A | N/A | N/A | May 5, 2020 | $715977 |
| Dec 31, 2019 | -$2.52 | -$1,040.00 | N/A | +99.76% | Beat | N/A | N/A | N/A | Mar 24, 2020 | $268514 |
| Sep 30, 2019 | -$449,999.77 | -$1,000,000.00 | N/A | +55.00% | Beat | N/A | N/A | N/A | Nov 7, 2019 | $333209 |
| Jun 30, 2019 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 14, 2019 | $209941 |
| Mar 31, 2019 | -$57,200.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 13, 2019 | $364232 |
| Dec 31, 2018 | -$1,000,000.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 27, 2019 | $299295 |
| Sep 30, 2018 | -$1.99 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 8, 2018 | $349344 |
| Jun 30, 2018 | -$2.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 7, 2018 | $93265 |
| Mar 31, 2018 | -$200,000.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 3, 2018 | $221299 |
| Dec 31, 2017 | -$200,000.00 | -$1,000,000.00 | N/A | +80.00% | Beat | N/A | N/A | N/A | Mar 23, 2018 | $179404 |
| Sep 30, 2017 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 9, 2017 | $247994 |
| Jun 30, 2017 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 7, 2017 | $352137 |
| Mar 31, 2017 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 8, 2017 | $295735 |
| Dec 31, 2016 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 24, 2017 | $174932 |
| Sep 30, 2016 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 11, 2016 | $440106 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$27.75, after -$75.27 the year before. It was -$3,749,302.88 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$27.75 | N/A |
| Dec 31, 2024 | -$75.27 | N/A |
| Dec 31, 2023 | -$357.25 | N/A |
| Dec 31, 2022 | -$258.95 | N/A |
| Dec 31, 2021 | -$197.52 | -174.4% |
| Dec 31, 2020 | $265.36 | N/A |
| Dec 31, 2019 | -$1,507,202.29 | N/A |
| Dec 31, 2018 | -$1,200,004.04 | N/A |
| Dec 31, 2017 | -$2,200,000.01 | N/A |
| Dec 31, 2016 | -$3,749,302.88 | N/A |
Earnings Calls
The 4 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 3,400 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q3 | Sep 30, 2025 | 3,441 | 8 | |
| 2025Q2 | Jun 30, 2025 | 4,525 | 9 | |
| 2025Q1 | Mar 31, 2025 | 4,230 | 7 | |
| 2024Q3 | Sep 30, 2024 | 6,874 | 13 |
2025Q3 Earnings Call
Opening remarks
David Dodd CEO Thank you. Welcome to the third quarter 2025 GeoVax corporate update. Following my comments, Mark Reynolds, our CFO, will provide an update of our financials, and then we will address any questions that you may have. We remain confident in the continued progress and compelling outlook for our portfolio of GEO-MVA, GEO-CM04S1, Gedeptin and the game-changing MVA vaccine manufacturing process. Each of our product development candidates address critically important unmet health care needs, providing opportunities for expedited registration paths and strong opportunities to commercialize differentiated solutions supporting patient needs worldwide. We also anticipate that the advanced MVA manufacturing process will provide a game-changing advantage in the production of MVA-based vaccines and therapies. We're experiencing increased partnering and collaboration interest from established industry players as well as increased interest from non-dilutive funding organizations, including stakeholders addressing various areas of worldwide vaccine needs. In June, we announced the receipt of guidance from the European Medicines Agency, referred to as the EMA, providing an expedited development path for GEO-MVA, our vaccine candidate against Mpox and Smallpox. This is most encouraging news in that it provides the potential for GeoVax to achieve marketing authorization and revenue generation sooner, allowing us to bypass Phase I and Phase II clinical trials and proceed directly to a Phase III immuno-bridging trial. As a result of this news, we're experiencing increased interest and dialogue with various industry colleagues and stakeholders regarding potential partnering, collaboration and funding. Relative to GEO-MVA, we have initiated the fill/finish of clinical batch vaccine material. We anticipate having vaccine available for clinical evaluation early next year. We're pleased to note that in addition to product in support of our clinical evaluation, we plan to produce additional product in support of potential use in conjunction with various stakeholder discussions that are underway. We believe that GEO-MVA provides the potential to end the current monopoly of MVA vaccine supply, expanding the global supply of this critically needed vaccine, addressing both the needs resulting from epidemic outbreaks as well as the various stockpile opportunities worldwide. Significant government interest exists relative to U.S.-based supply chains versus the current overdependence on non-U.S. suppliers. The strong sentiment in favor of such onshoring initiatives is a major national legislative focus and interest. We remain in active discussions and briefings with various stakeholders, including the White House, Congressional Representatives, HHS, WHO, the International Vaccine Institute, the Africa CDC and others regarding our progress relative to cGMP clinical inventory of GEO-MVA. In fact, this was the subject of numerous discussions during our recent series of meetings in Europe in conjunction with the World Vaccine Congress Europe, BIO-Europe and individual meetings held in Geneva and elsewhere.
Frequently Asked Questions About GOVX
When is GeoVax Labs's next earnings date?
GeoVax Labs's next earnings report is expected for Apr 13, 2027.
Did GOVX beat earnings estimates last quarter?
Yes. GeoVax Labs reported EPS of -$10.56 for the quarter ended Sep 30, 2026, above the -$24.58 estimate, a 57.04% surprise.
What EPS do analysts expect from GOVX next quarter?
The consensus EPS estimate for GeoVax Labs for the quarter ending Dec 31, 2026 is -$29.38 from 3 analysts.
How often does GOVX beat earnings estimates?
GeoVax Labs beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +1.16%.
GOVX pages: Overview, Earnings, Forecast, Financials, Competitors